Everolimus

• Tablets 250micrograms, 750micrograms, 2.5mg, 5mg, 10mg

Notes

1. NICE TA421: Everolimus (Afinitor), in combination with exemestane, is recommended within its marketing authorisation, as an option for treating advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women without symptomatic visceral disease that has recurred or progressed after a non-steroidal aromatase inhibitor. Everolimus is recommended only if the company provides it with the discount agreed in the patient access scheme (December 2016).
2. NICE TA432: Everolimus (Afinitor) is recommended within its marketing authorisation as an option for treating advanced renal cell carcinoma that has progressed during or after treatment with vascular endothelial growth factor targeted therapy, only if the company provides it with the discount agreed in the patient access scheme (February 2017).
3. NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (June 2017):
   1. Everolimus (Afinitor) and sunitinib (Sutent) are recommended within their marketing authorisations, as options for treating well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease.
   2. Everolimus (Afinitor) is recommended, within its marketing authorisation, as an option for treating well-differentiated (grade 1 or grade 2) non-functional unresectable or metastatic NETs of gastrointestinal or lung origin in adults with progressive disease.
   3. Everolimus is recommended only when the company provides it with the discount agreed in the patient access scheme.
4. NICE TA498: Lenvatinib (Kisplyx) plus everolimus is recommended as an option treating advanced renal cell carcinoma in adults who have had 1 previous vascular endothelial growth factor (VEGF)-targeted therapy, only if their Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1 (January 2018).
5. NICE TA348: Everolimus (Certican) is not recommended within its marketing authorisation for preventing organ rejection in liver transplantation (July 2015).
6. NICE TA481: Everolimus (Certican) is not recommended as an initial treatment to prevent organ rejection in adults having a kidney transplant. (October 2017).
7. NICE TA482: Everolimus (Certican) is not recommended as an initial treatment to prevent organ rejection in children and young people having a kidney transplant. (October 2017).

Temsirolimus

• NICE TA178: Bevacizumab (Avastin), sorafenib (Nexavar), and temsirolimus (Torisel) are not recommended as first-line treatment options for people with advanced and/or metastatic renal cell carcinoma (August 2009).